Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologus rapamycin resistant T-cell therapy - Rapa Therapeutics

Next Previous
X
Search
Drug Profile

Autologus rapamycin resistant T-cell therapy - Rapa Therapeutics

Alternative Names: Autologous rapamycin resistant Th1/Tc1 cells; Autologous rapamycin resistant Th1/Tc1 cells - RAPA Therapeutics; Autologous rapamycin-resistant Th1/Tc1 (RAPA-201) cell therapy; RAPA 201 autologus cell therapy; RAPA-201 autologous T cells; RAPA-201 cells; RAPA-201 T-cell therapy - Rapa Therapeutics

Latest Information Update: 29 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rapa Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma; Solid tumours

Most Recent Events

  • 11 Dec 2021 Adverse events, efficacy and pharmacodynamics data from a phase II trial in Multiple myeloma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 01 Aug 2021 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Recurrent) in USA (Parenteral) (NCT05144698)
  • 01 Aug 2021 Autologus rapamycin resistant T-cell therapy - Rapa Therapeutics receives Fast Track designation for Multiple myeloma [Parenteral] (Second-line therapy or greater) in USA (NCT05144698)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top